Related Experiment Video

Updated: Jul 15, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
14:23

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

15.7K

Effectiveness and Safety of SARS-CoV-2 Vaccination in HIV-Infected Patients-Real-World Study

Monika Bociąga-Jasik1,2, Martyna Lara2, Aleksandra Raczyńska2

  • 1Department of Infectious and Tropical Diseases, Jagiellonian University Medical College, 30-688 Krakow, Poland.

Vaccines
|May 27, 2023
PubMed

Insights

COVID-19 vaccines are safe and effective in people with HIV (PLWH). mRNA vaccines, particularly mRNA-1273, induced the strongest humoral and cellular immune responses in this high-risk group.

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Assessing COVID-19 vaccine immunogenicity in high-risk populations like people living with HIV (PLWH) is crucial.
  • Biomedical research has achieved significant success in COVID-19 vaccine development, but challenges remain.

Purpose of the Study:

  • To evaluate the immunogenicity and safety of COVID-19 vaccines in people living with HIV (PLWH).
  • To compare the humoral and cellular immune responses induced by different COVID-19 vaccine types in PLWH.

Main Methods:

  • 121 PLWH aged over 18 were enrolled in the Polish National Vaccination Program.
  • Humoral immunity was assessed using ELISA for IgG antibodies against the SARS-CoV-2 S1 protein.
  • Cellular immunity was measured by interferon-gamma release assay (IGRA) to quantify interferon-gamma (IFN-γ).

Main Results:

  • 95% (78.5%) of vaccinated PLWH developed protective IgG antibody levels.
  • Only 6.6% of PLWH did not develop a cellular immune response.
  • mRNA-1273 vaccine demonstrated the best humoral and cellular immune responses compared to other vaccines.

Conclusions:

  • COVID-19 vaccines are immunogenic and safe for people living with HIV (PLWH).
  • mRNA vaccines, especially mRNA-1273, are associated with superior humoral and cellular immune responses in PLWH.

Keywords:
COVID-19HIVimmunogenicityvaccination

More Related Videos

An In Vitro Model for Measuring Immune Responses to Malaria in the Context of HIV Co-infection08:14

An In Vitro Model for Measuring Immune Responses to Malaria in the Context of HIV Co-infection

Published on: October 6, 2015

10.3K
Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses05:49

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

1.8K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...